By Vincent Joralemon As therapies using drugs like MDMA, psilocybin, and LSD advance through the FDA research and approval pipeline, patients should be prepared for steep price tags attached to these procedures. For example, experts estimate MDMA-assisted therapy for PTSD will cost upwards of $12,000 per patient. These high costs highlight the need for comprehensive…
There is little consensus in defining “psychedelic.” Yet, research on and access to these substances hinges on what gets included under this umbrella.
The parity framework has proven less adept at rooting out more subtle forms of disparities in mental health coverage restrictions.
There are many highly-trained physicians in the world who would be happy to work in the U.S. Why not let them in and introduce some free-market competition?
Expanding health insurance coverage may be on the menu through budget reconciliation.
Our government bails out large risks in many arenas. Yet we fail to backstop the most human risk of all — our vulnerability to suffering and death.
The Biden administration should offer employers a Medicare-based public health insurance option for their employee coverage.
The focus of the nascent Biden administration has been on making private health insurance more durable, not deconstructing it.
By Oliver Kim Last year, I had the good fortune to present at the Petrie-Flom Center’s conference on transparency and I started with an anecdote about a congressman who decided to wait rather than take his son immediately to the emergency room after he injured himself. The congressman assumed his son only had a sprain,…
Guest post by Erin Fuse Brown [Cross-posted from Center for Law, Health and Society Blog] Commentators have been weighing in since the Supreme Court decided it would hear King v. Burwell, the case challenging the ability of millions of Americans to receive subsidies to purchase health insurance on federally operated Exchanges under the ACA. Debate swirls over whether a…
